Biosion USA, Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with ImmunoGen. In the joint research effort, Biosion will leverage its proprietary SynTracer high-throughput (HT) endocytosis platform to generate highly selective antibodies to targets allocated by each company and ImmunoGen will provide their proprietary linker-payload technology to create novel ADCs.
“We are excited about our new joint research effort with ImmunoGen, a world-renowned leader in ADCs,” said Hugh Davis, Ph.D., Chief Operating Officer, and President of Biosion USA, Inc. “This collaboration will take advantage of the strengths of each company; ImmunoGen’s expertise in linkers and payloads combined with Biosion’s SynTracer HT endocytosis platform with the goal of identifying novel treatments for solid tumor cancers.”